The joint Nuclear Medicine department of the University hospital of Nantes and the ICO has all the expertise required to carry out clinical trials in the fields of imaging, dosimetry and molecular radiotherapy in oncology, cardiology and neurology: radiolabelling, automated synthesis machines, SPECT-CT, PET-CT, shielded chambers.
PET – view taken at the ICO
The In-house Hospital Radioiopharmacy (APUI) of the University Hospital of Nantes, located in Arronax, is equipped with shielded cells, quality control instruments and automatic systems for the purification, synthesis and distribution of radioisotopes and radiopharmaceuticals for clinical trials in local and national clinical centres.
Ongoing clinical trial as of May 1, 2022 :
- 64Cu-ATSM PET/CT in Rectum Cancer (TEP 64Cu-ATSM-Rectum) (sponsor : Western Cancer Institute – ICO)
- Development and regulatory submission for the compound 177Lu-Pentixather involved in 2 clinical trials financed by Nantes University Hospital and due to start in the first half of 2022 :
– Pentilula : phase I/II study evaluating radiotherapy with the radiolabeled ligand 177Lu-pentixather in patients with relapsed or refractory CXCR4+ acute leukemia
– Pentallo : phase 1 study testing the 177Lutetium-pentixather radioligand prior to allograft transplantation in acute myeloid leukemia/acute lymphocytic leukemia patients with CXCR4 in second remission
APUI production chambers in Arronax